Gallery
| Structures | ||
| All images in this section may be used without permission provided attribution is given. | ||
CYP11B2 binding the Cushing's drug osilodrostat
|
CYP11B2 binding adrenodoxin and fadrazole inhibitor
|
CYP17A1 binding a steroidal isonitrile
|
Cytochrome P450 17A1 with the prostate cancer drug abiraterone (Zytiga®).
|
Human cytochrome P450 1A1 with alpha-naphthoflavone.
|
CYP1A1 binding cancer drug erlotinib
|
Human cytochrome P450 2A13.
|
Human cytochrome P450 2A6.
|
Comparison of cytochrome P450 2A13 and 2A6 active sites.
|
CYP3A7 (fetal CYP3A) with 4 copies of its DHEAS substrate
|
CYP8B1 active site with tioconazole and glycerol (grey sticks)
|
Comparison of human cytochrome P450 enzyme active sites.
|
Cytochrome P450 2A6 I208S / I300F / G301A / S369G mutant with phenacetin.
|
Electron density for flavin mononucleotide in NADPH-cytochrome P450 reductase
|
Histamine dehydrogenase from Nocardioides simplex.
|
Human cytochrome P450 2E1 secondary structure.
|
Human cytochrome P450 2E1 with 4-methypyrazole.
|
Human cytochrome P450 2E1 with indazole.
|
Proline 4-hydroxylase from Bacillus anthracis.
|
NADPH-Cytochrome P450 reductase FMN-containing domain with FMN in black sticks
|
Cytochrome P450 2B4 movie morphing between open and closed conformations.
|